Puma Biotechnology Inc (PBYI) Company Cash on Hand

PBYI (Puma Biotechnology, Inc.) - company brandmark

Puma Biotechnology generates revenue from breast cancer recurrence therapy, ensuring a stable income stream. The daily price action of the company's cash position on the GURU.Markets chart demonstrates liquidity, where the 0.11 level captures the current state. International partnerships in Asia and Europe mitigate risks, although declining sales of the primary drug necessitate strict control over the internal funding of new developments.

PBYI - Puma Biotechnology Company Cash Funds over the range 07/04/2022 - 11/21/2026

Summary analytical data breakdowns for Puma Biotechnology, Inc. (PBYI)

Summary company analysis:Puma Biotechnology, Inc.
Signature product of pumabiotechnology.com

The investment attractiveness of Puma Biotechnology (PBYI) is based on exclusive rights to a breast cancer drug, which ensure high margins. This metric measures the volume of liquid assets generated through operating activities and interest income to maintain financial stability. By analyzing changes in the cash balance on the GURU.Markets platform, an investor can distinguish short-term volatility from the fundamental strength of the business. Sufficient capital guarantees protection against market shocks and the stable development of the company.